Understanding how STING affects the progression and treatment of chronic lymphocytic leukemia.
Official title: Mechanisms of STING in malignant progression and therapy of CLL.
Funded at Methodist Hospital Research Institute · NIH-11030220 · Data updated 2026-11-12
This study is looking at how a protein called STING can help boost the immune system to fight chronic lymphocytic leukemia (CLL) better, especially when used with current treatments, to find new ways to improve care for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $442,928 |
| NIH project number | 5R01CA269835-03 |
| Project ID | NIH-11030220 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with chronic lymphocytic leukemia, particularly those who have experienced adverse effects from current therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with chronic lymphocytic leukemia may not benefit from this research.
What this research studies
This research investigates the role of the STING protein in chronic lymphocytic leukemia (CLL), a common type of adult leukemia. It aims to explore how STING can enhance immune responses and potentially improve treatment outcomes for patients. The study will examine the effects of STING agonists, which are compounds that activate STING, in combination with existing therapies like Bruton's tyrosine kinase inhibitors (BTKi). By understanding these mechanisms, the research seeks to develop novel therapeutic strategies that could directly target CLL or enhance the effectiveness of current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for chronic lymphocytic leukemia, potentially reducing adverse effects and improving patient outcomes.
How similar studies have gone: Previous research has shown promising results using STING agonists in treating various cancers, indicating potential for success in this novel application for CLL.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Hu, Chih-Chi Andrew — Methodist Hospital Research Institute
- Study coordinator: Hu, Chih-Chi Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.